Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 293-304

  Koh, Valerie Cui Yun ^a   Lim, Jeffrey Chun Tatt ^a   Thike, Aye Aye ^a   Cheok, Poh Yian ^a   Thu, Minn Minn Myint ^a   Tan, Veronique Kiak Mien ^b   Tan, Benita Kiat Tee ^a   Ong, Kong Wee ^b   Ho, Gay Hui ^b   Tan, Wai Jin ^a   Tan, Yongcheng ^a   Salahuddin, Ahmed Syed ^a   Busmanis, Inny ^a   Chong, Angela Pek Yoon ^a   Iqbal, Jabed ^a   Thilagaratnam, Shyamala ^c,d   Wong, Jill Su Lin ^b   Tan, Puay Hoon ^a,e,f  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c Health Promotion Board Singapore   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Clinicopathological parameters; DCIS; Immunohistochemistry; Recurrence; Screen detected; Survival; Symptomatic

Indexed keywords

CYTOKERATIN 14; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LUMINAL A BREAST CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATIC PATIENT; TREND STUDY; TUMOR INVASION; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY CANCER DIAGNOSIS; MAMMOGRAPHY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR BURDEN;

EID: 84954528904     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3472-6     Document Type: Article

References (56)

1. Silverstein MJ (1998) Ductal carcinoma in situ of the breast. BMJ 317(7160):734–739
2. Frykberg ER, Bland KI (1994) Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74(1 Suppl):350–361
3. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/. Accessed 5 April 2014
4. Jara-Lazaro AR, Thilagaratnam S, Tan PH (2010) Breast cancer in Singapore: some perspectives. Breast Cancer 17(1):23–28. doi:10.1007/s12282-009-0155-3
5. Jorgensen KJ, Keen JD, Gotzsche PC (2011) Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 260(3):621–627. doi:10.1148/radiol.11110210
6. Welch HG, Woloshin S, Schwartz LM (2008) The sea of uncertainty surrounding ductal carcinoma in situ–the price of screening mammography. J Natl Cancer Inst 100(4):228–229. doi:10.1093/jnci/djn013
7. Coldman A, Phillips N (2013) Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ 185(10):E492–E498. doi:10.1503/cmaj.121791
8. Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010(41):139–141. doi:10.1093/jncimonographs/lgq027
9. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J (2005) Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7(6):258–265. doi:10.1186/bcr1354
10. Moss S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 7(5):230–234. doi:10.1186/bcr1314
11. Paci E, Duffy S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res 7(6):266–270. doi:10.1186/bcr1339
12. Kopans DB, Smith RA, Duffy SW (2011) Mammographic screening and “overdiagnosis”. Radiology 260(3):616–620. doi:10.1148/radiol.11110716
13. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39(12):1746–1754
14. Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP Jr, Schnitt SJ, Habel LA (2013) Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat 139(2):453–460. doi:10.1007/s10549-013-2539-5
15. Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31(32):4054–4059. doi:10.1200/JCO.2013.49.5077
16. Zhang X, Dai H, Liu B, Song F, Chen K (2015) Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev. doi:10.1097/CEJ.0000000000000131
17. Lakhani SR, Ellias IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO classification of tumours of the breast, 4th edn. IARC, Lyon
18. Tan PH (2001) Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding. Ann Acad Med Singap 30(6):671–676 quiz 677
19. Thike AA, Iqbal J, Cheok PY, Tse GM, Tan PH (2013) Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol 66(8):665–670. doi:10.1136/jclinpath-2012-201428
20. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23(1):123–133. doi:10.1038/modpathol.2009.145
21. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168
22. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984
23. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492
24. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS, Tan PH (2010) Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 34(7):956–964. doi:10.1097/PAS.0b013e3181e02f45
25. Health Promotion Board (2015) BreastScreen Singapore. http://www.hpb.gov.sg/HOPPortal/programmes-article/3324. Accessed 26 Jan 2015
26. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271
27. Kong I, Narod SA, Taylor C, Paszat L, Saskin R, Nofech-Moses S, Thiruchelvam D, Hanna W, Pignol JP, Sengupta S, Elavathil L, Jani PA, Done SJ, Metcalfe S, Rakovitch E (2014) Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 21(1):e96–e104. doi:10.3747/co.21.1604
28. Barnes NL, Dimopoulos N, Williams KE, Howe M, Bundred NJ (2014) The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast. Eur J Surg Oncol 40(3):249–254. doi:10.1016/j.ejso.2013.12.013
29. Ma KK, Lau SS, Cheung PS (2013) Ductal carcinoma in situ in Chinese women undergoing opportunistic breast cancer screening. Surg Pract 18(1):8–14. doi:10.1111/1744-1633.12042
30. Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151
31. Kessar P, Perry N, Vinnicombe SJ, Hussain HK, Carpenter R, Wells CA (2002) How significant is detection of ductal carcinoma in situ in a breast screening programme? Clin Radiol 57(9):807–814
32. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76(7):1197–1200
33. Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49(4):751–758
34. Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12):2481–2484. doi:10.1002/cncr.21069
35. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239(18):1863–1867
36. Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96(12):906–920
37. Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036. doi:10.1200/JCO.2005.02.9975
38. Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186(4):337–343
39. Sue GR, Chagpar AB (2015) Predictors of recurrence in patients diagnosed with ductal carcinoma in situ. Am Surg 81(1):48–51
40. Evans A (2003) The diagnosis and management of pre-invasive breast disease: radiological diagnosis. Breast Cancer Res 5(5):250–253. doi:10.1186/bcr621
41. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637. doi:10.1093/jnci/djq101
42. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE (2003) Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39(5):622–630
43. Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 30(3):243–247. doi:10.1016/j.ejso.2003.11.004
44. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691. doi:10.1200/JCO.2009.24.9284
45. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 104(1):120–127. doi:10.1038/sj.bjc.6606021
46. Zhou W, Jirstrom K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Warnberg F (2010) Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 10:653. doi:10.1186/1471-2407-10-653
47. Zhou W, Jirstrom K, Amini RM, Fjallskog ML, Sollie T, Lindman H, Sorlie T, Blomqvist C, Warnberg F (2013) Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 13:512. doi:10.1186/1471-2407-13-512
48. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38(2):197–204. doi:10.1016/j.humpath.2006.08.017
49. Dabbs DJ, Chivukula M, Carter G, Bhargava R (2006) Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 19(11):1506–1511. doi:10.1038/modpathol.3800678
50. Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A (2013) Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Res Treat 141(1):145–154. doi:10.1007/s10549-013-2670-3
51. Wong FY, Wang F, Chen JJ, Tan CH, Tan PH (2014) Outcomes of low-risk ductal carcinoma in situ in Southeast Asian women treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 88(5):998–1003. doi:10.1016/j.ijrobp.2014.01.018
52. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM (2005) Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200(4):516–526. doi:10.1016/j.jamcollsurg.2004.11.012
53. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM (2011) Ductal carcinoma-in situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 18(10):2873–2878. doi:10.1245/s10434-011-1707-2
54. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953–958
55. Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44(12):2684–2689. doi:10.1016/j.humpath.2013.07.010
56. Parikh RR, Haffty BG, Lannin D, Moran MS (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82(1):7–13. doi:10.1016/j.ijrobp.2010.08.027